Category: Retrophin

BiotechDueDiligence Reading List

9/27/2014

Legislation Would Prevent Drug Makers From Thwarting Generic Rivals
Ed Silverman (Pharmalot / WSJ) $RTRX (and others)

A great investing quote, and how it relates to recent biotech IPOs
Brad Loncar (Loncar Blog)

Finding Risks, Not Answers, in Gene Tests
Denise Grady and Andrew Pollack (New York Times)

"Forced switch" maneuver spurs lawsuit against drug maker
Jonathan Lapook (CBS News)

FierceBiotech 2014 Fierce 15
"12th annual take on some of the most noteworthy private biotech upstarts making headway these days" - John Carroll, Editor

Biology: Three Known Unknowns
Katherine Bourzac (Scientific American)
"Even as cancer therapies improve, basic questions about drug resistance, tumour spread and the role of normal tissue remain unanswered"

Nutrition: Vitamins on trial
Melinda Wenner Moyer (Nature News)
"After decades of study, researchers still can't agree on whether nutritional supplements actually improve health"

0 Comments

Biotech Reading List

8/3/2014

0 Comments

The Coming Human Body On A Chip That Will Change How We Make Drugs
Jessica Leber (Fast Co Exist)
On the search for non-animal alternatives for predicting drug effects / toxicology in humans.

How Well Does A Drug Work? Look Beyond The Fine Print
National Public Radio
Can we improve drug labeling so patients actually understand how well the drug works, compared to what, and with what side effects?

These Medical Apps Have Doctors and the FDA Worried
Robert McMillan (Wired)

Does Valeant’s Cost-Cutting Go Too Far?
Jesse Eisenger (ProPublica) $VRX $AGN

With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan
Alex Nash (Xconomy) $RTRX

Interview: Steve Yang (WuXi AppTec) on the Chinese biotech industry
Partnering 360

0 Comments

BiotechDueDiligence Reading List

5/5/2014

0 Comments

Continue reading below for a new and super-sized collection of recent links that I believe would be of interest the biotech enthusiast. This is not intended to be a summary of the "news" but to capture the story lines and conversations that are dominating the discussion and moving biotech and pharmaceutical stocks at the moment. Catch up on previous editions in the archives.

0 Comments

New stock research page: Retrophin $RTRX

2/15/2013

0 Comments

I am pleased to announce that a BiotechDueDiligence stock research page for Retrophin $RTRX - the newly public biotech company headed by Martin Shkreli - is live.

Retrophin's lead drug, RE-021 for FSGS, is licensed from Ligand Pharma LGND (a long-time BDD favorite) and Bristol Myers Squibb BMY. The drug candidate is a vestige of a Pharmacopeia PCOP - Schering Plough SGP drug discovery alliance.

The Retrophin page features a complete slide deck from the company's recent presentation at the 2013 BIO CEO conference, along with extensive notes that I took while listening to the webcast. It all adds up to a great introduction to this new biotech player in the orphan disease arena.

RTRX also now has an entry on the Biotech Cash and Valuation page, where you'll find info on shares outstanding, net cash balance, and real-time valuation metrics for dozens of biotech stocks.

0 Comments

BiotechDueDiligence Reading List

Biotech Reading List

BiotechDueDiligence Reading List

New stock research page: Retrophin $RTRX

Categories

Archives